Drug Type Small molecule drug |
Synonyms (3aS,4R,9bR)-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta(c)(1) benzopyran-8-ol, Erteberel (USAN/INN), LY 500307 + [2] |
Target |
Mechanism ERβ agonists(Estrogen receptor beta agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H18O3 |
InChIKeyXIESSJVMWNJCGZ-VKJFTORMSA-N |
CAS Registry533884-09-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depression | Phase 2 | US | 23 May 2019 | |
Depressive Disorder | Phase 2 | US | 23 May 2019 | |
Hypertrophy | Phase 2 | US | 01 Apr 2010 | |
Hypertrophy | Phase 2 | AU | 01 Apr 2010 | |
Hypertrophy | Phase 2 | CA | 01 Apr 2010 | |
Hypertrophy | Phase 2 | FR | 01 Apr 2010 | |
Hypertrophy | Phase 2 | DE | 01 Apr 2010 | |
Hypertrophy | Phase 2 | GR | 01 Apr 2010 | |
Hypertrophy | Phase 2 | IT | 01 Apr 2010 | |
Hypertrophy | Phase 2 | RU | 01 Apr 2010 |
Phase 2 | 95 | (LY500307 150mg) | kqvdhqicmk(bbdujjkwbl) = qcknxrovie vxvvlxlgso (eucxmrhxpz, qdninjaglj - rbzfhsslpd) View more | - | 02 Jul 2019 | ||
Placebo (Placebo) | kqvdhqicmk(bbdujjkwbl) = vpbismcbbo vxvvlxlgso (eucxmrhxpz, ewotxhnoue - btpdbscqnw) View more | ||||||
Phase 2 | 414 | Placebo | csxwmvquxq(zrzxaiksvl) = zdpulhfrio ltvzpzaask (jjbbbuehzc, cckvcnlfdf - aphpffffkq) View more | - | 08 Apr 2019 |